With respect to the mechanism underlying induction of synthetic lethality by simultaneous inhibition of CBP/p300 in SMARCB1-deficient cancers, we found that localization of the BAF and PBAF complexes, including SMARCB1, to the promotor region of the KREMEN2 gene locus leads to transcriptional repression of the KREMEN2 gene; this is because deficiency of SMARCB1 leads to an increase in expression of KREMEN2 by allowing CBP/p300 to localize at the promotor region. The gene discussed is KREMEN2; the disease is cancer.